Paul Gougis

机构：Inserm, Université Paris Cité, Sorbonne Université, Assistance Publique – Hôpitaux de Paris, Immunité et Cancer, Pitié-Salpêtrière Hospital, Institut Curie · ORCID：0000-0003-3064-7043

发表论文 201 篇 · 总被引 2272 次 · h-index 22

代表论文

• CXCR6 + T Cells Drive Immune Checkpoint Inhibitor Myocarditis (2026 · Circulation · 被引 13)
• Outcomes of Anastrozole, Letrozole, and Exemestane in Patients With Postmenopausal Breast Cancer (2025 · JAMA Network Open · 被引 5)
• Time-related biases in observational studies : an illustration with COVID-19 vaccination during immune checkpoint inhibitor therapy (2025 · medRxiv · 被引 4)
• Maternal and Neonatal Complications Associated with Breast Cancer Systemic Treatments—A VigiBase Disproportionality Analysis Study (2026 · Clinical Pharmacology & Therapeutics · 被引 1)
• BOS172738, a selective RET inhibitor, for the treatment of patients with RET-altered tumors including RET-fusion-positive non-small-cell lung cancer and RET-mutant medullary thyroid cancer: a phase I dose-escalation/expansion multicenter study (2025 · ESMO Open · 被引 1)
• REINFORCE: A phase III randomized trial of treatment intensification with docetaxel in metastatic hormone-sensitive prostate cancer patients without deep PSA response after initial apalutamide therapy. (2026 · Journal of Clinical Oncology)